Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05618041
Other study ID # 20221019
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 7, 2022
Est. completion date December 6, 2024

Study information

Verified date November 2022
Source Hebei Senlang Biotechnology Inc., Ltd.
Contact Shengmin Guo
Phone 008618633039369
Email guoshengmin@senlangbio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the tolerability and safety of CAR-T technology in patients with relapsed or refractory hematolymphoid malignancies.


Description:

Main research purposes: To evaluate the tolerability and safety of CAR-T technology in patients with relapsed or refractory hematolymphoid malignancies. Secondary research purposes: Objective Evaluation of Cytodynamic Characteristics of CAR-T in Different Types of Hematological Malignancies


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date December 6, 2024
Est. primary completion date September 6, 2024
Accepts healthy volunteers No
Gender All
Age group 14 Years to 75 Years
Eligibility Inclusion Criteria: - Sign the informed consent and be willing and able to comply with the visit, treatment protocol, laboratory examination, and other requirements of the study as specified in the study procedure sheet; - Diagnosed as recurrent or refractory lymphoma, leukemia or myeloma; - Tumor cells express targets for CAR-T cell therapy (results: flow cytometry or Immunohistochemical test confirmation); - Age 14-75 (including threshold), gender unlimited; - Eastern Cooperative Oncology Group (ECOG) score =2; - HGB = 70g/L (blood transfusion allowed); - Liver and kidney functions, heart and lung functions meet the following requirements: 1. Creatinine = 1.5 × ULN; 2. Left ventricular ejection fraction = 50%; 3. Blood oxygen saturation>90%; 4. Total bilirubin = 1.5 × ULN; ALT and AST = 2.5 × ULN; - For T cell tumor patients, if tumor cells are detected in peripheral blood during screening, flow cytometry should be used to detect that the tumor cell surface immunophenotype is CD4 and CD8 double negative. If the immunophenotype of peripheral blood tumor cells is not double negative for CD4 and CD8, the condition that the proportion of peripheral blood tumor cells is = 1% shall be met; - Subjects with pregnancy plans must agree to use contraception before entering the study and after the study lasts for six months; If the subject is pregnant or suspected of being pregnant, the investigator shall be informed immediately; - The subject or guardian understands and signs the informed consent form; - Expected survival longer than 3 months. Exclusion Criteria: - Severe cardiac insufficiency; - Have a history of severe lung impairment; - Complicated with other advanced malignant tumors; - Complicated with severe or persistent infection that cannot be effectively controlled; - Complicated with severe autoimmune diseases or congenital immune deficiency; - Active hepatitis (HBV DNA or HCV RNA positive); - Human immunodeficiency virus (HIV) infection or syphilis infection; - Have a history of severe allergy to biological products (including antibiotics); - If there is a history of hematopoietic stem cell transplantation, it should be no more than 6 months before the patient receives allogeneic hematopoietic stem cell transplantation; - Subjects who received CAR-T therapy or other gene modified cell therapy before screening; - Conditions that the investigator believes may increase the risk to the subject or interfere with the outcome of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
CAR-T Autologous T cell injection
Biological: CAR-T; Drug: Cyclophosphamide,Fludarabine;Procedure: Leukapheresis

Locations

Country Name City State
China Shanxi Bethune Hospital Taiyuan Shanxi

Sponsors (1)

Lead Sponsor Collaborator
Hebei Senlang Biotechnology Inc., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety: Incidence and severity of adverse events To evaluate the possible adverse events occurred within first one month after CAR-T infusion, including the incidence and severity of symptoms such as cytokine release syndrome and neurotoxicity First 1 month post CAR-T cells infusion
Primary Efficacy: Remission Rate Complete remission (CR) Complete remission with incomplete recovery of blood cells (CRI), positive minimal residual tumor (MRD+) or negative tumor (MRD -) CR/CRI, disease recurrence or progression (PD) were evaluated, and the overall remission rate was ORR=CR+CRI; For drenching Complete remission (CR), partial remission (PR), disease stability (SD) Disease recurrence or progression (PD) was evaluated, and the overall remission rate was ORR=CR+PR; For multiple myeloma Complete remission (CR), partial remission (VGPR, PR), disease stability (SD), disease recurrence or progression (PD) were adopted, Overall remission rate ORR=CR+VGPR+PR; 3 months post CAR-T cells infusion
Secondary progression-free survival (PFS) progression-free survival (PFS) time 24 months post CAR-T cells infusion
Secondary CAR-T proliferation the copy number of Senl CAR- T cells in the genomes of PBMC by qPCR method 3 months post CAR-T cells infusion
Secondary Cytokine release Cytokine( IL-6,IL-10,IFN-?,TNF-a ) concentration (pg/mL) by flow cytometry method 1 month post CAR-T cells infusion
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1
Recruiting NCT04111809 - Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care